Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Ironwood Pharmaceuticals, Inc. (IRWD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
22Total relationships
4Distinct source URLs
12High confidence
0.821Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Ironwood Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
FERRING-INTERNATIONAL-CENTER-S-A
FERRING-INTERNATIONAL-CENTER-S-A
92%
The Amendment provides for a payment by VectivBio of $12.5 million, in the aggregate, to Ferring
WELLS-FARGO-BANK-NATIONAL-ASSOCIATION
WELLS-FARGO-BANK-NATIONAL-ASSOCIATION
90%
On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement
Reciprocal relationship from CYCN graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from CYCN graph: ted of the following (in thousands): March 31, December 31, 2026 2025 Profes…
Reciprocal relationship from JAGX graph: suant to Chapter 34 Table of Contents 11 of the US Bankruptcy Code. The rights to crofelemer and the botanical extract used in Equilevia and Neonorm, as well …
Reciprocal relationship from NEUP graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from NEUP graph: obtain regulatory approvals, manufacture a commercial scale product, or arra…
. Hanmi Pharmaceutical is also developing a GLP-2 analog, to be administered once a month, and which is being evaluated in a Phase II clinical trial. Products with other mechanisms of action may emer…
Reciprocal relationship from ORANY graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from ORAN…
ZLDPF
Zealand Pharma A/S
72%
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: example, for apraglutide, we compete with companies that are commercializing or developing drugs for SBS, such as Ta…
ZLDPF
Zealand Pharma A/S
72%
example, for apraglutide, we compete with companies that are commercializing or developing drugs for SBS, such as Takeda, which currently distributes the GLP-2 analog teduglutide, marketed as GATTEX®…
Reciprocal relationship from ABBV graph: Reciprocal relationship from IRWD graph: The Company records royalties on sales of CONSTELLA in Canada and LINZESS in Mexico in the period earned.
ASTELLAS-PHARMA-INC
ASTELLAS-PHARMA-INC
92%
Under the license agreement, as amended, Astellas is required to pay royalties to the Company at rates beginning in the mid-single digit percent and escalating to low-double-digit percent, based on a…
Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD graph: Under the collaboration agreement, As…
Under the collaboration agreement, AstraZeneca is required to pay tiered royalties to the Company at rates beginning in the mid-single-digit percent and increasing up to twenty percent based on the a…
Reciprocal relationship from NEUP graph: obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf or conduct sales and marketing activi…
ZLDPF
Zealand Pharma A/S
72%
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: products and to leverage our exis…
ZLDPF
Zealand Pharma A/S
72%
products and to leverage our existing capabilities to develop and commercialize these products in the U.S. We have pursued a partnering strategy for commercializing linaclotide that has allowed us to…
Ironwood Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IRWD-DEBT-10370
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-12-31.
IRWD-DEBT
Debt stack $320.2M
90%
Market cache reports total debt of $320.2M.
IRWD-DEBT-10369
Warrants outstanding: 18.82
90%
xbrl warrant detail from xbrl 2023-12-31.
Ironwood Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Ironwood Pharmaceuticals, Inc..
Ironwood Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
IRWD-OWNER-ARMISTICE-CAPITAL-LLC
ARMISTICE CAPITAL, LLC
90%
13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 227 tracked holders.
Ironwood Pharmaceuticals, Inc. Extended Supply Chain Network
